SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : E-FoodSafety (EFSF)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: strike_1 who wrote (2)1/24/2006 12:04:30 AM
From: strike_1  Read Replies (1) of 47
 
eFoodSafety.com Inc. Announces Expansion of Marketing Program for Clinically Proven Diabetes/Hypoglycemic Product
Thursday December 22, 11:00 am ET
Cinnergen(TM) to Begin National Television Advertising Campaign

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Dec. 22, 2005--Patricia Ross-Gruden, president and CEO of eFoodSafety.com Inc. (OTCBB: EFSF - News), announced today that due to the favorable response to the current direct response radio campaign promoting Cinnergen(TM) (www.cinnergen.com), the company will now commence with a national television advertising campaign in order to widen even further the availability of this product formulated to assist the body in metabolizing blood sugar. She further stated that the response and acceptance of this product in this $132 billion market is extremely gratifying in that it is a product widely needed in the diabetes/hypoglycemic market, and is a large step toward profitability for the company.

Cinnergen(TM) is a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar or calories. Cinnergen(TM) is specially formulated to promote healthy glucose metabolism and has been clinically proven to decrease the symptoms that commonly accompany elevated blood sugar and its effects.

Cinnergen(TM) delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. As a whole food complex, Cinnergen(TM) provides several key ingredients that are generally deficient in a typical American diet and that have been proven clinically through years of research to improve digestion and utilization of sugar to help treat the symptoms of type 2 diabetes, hypoglycemia or insulin resistance.

"We anticipate that the company's third quarter ending Jan. 31, 2006, will begin to reflect sales revenues from our Cinnergen(TM) product, while we further predict double-digit sales revenue increases for the remaining quarters of 2006," added Ross-Gruden.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext